CareTalk: Healthcare. Unfiltered. · 2026-06-10 · 3 min
Key moments - from our scoring
Substance score
4 / 100
Five dimensions, 20 points each
The episode centers on a pivotal scientific insight about insulin physiology and hepatic glucose metabolism. Drawing on tracer studies in laboratory rats, the discussion examines how insulin functions in the body and the liver's role in glucose storage during meals. The key revelation involves understanding why insulin fails to reach the liver through peripheral administration, a phenomenon that fundamentally challenges conventional assumptions in endocrinology. This research appears to have emerged from personal motivation - the host or primary subject's type 1 diabetes diagnosis - which redirected their career toward investigating this specific metabolic pathway. The episode would resonate with healthcare operators, researchers in endocrinology, and anyone involved in diabetes management or insulin therapy development, as it addresses a core mechanistic gap in how we understand insulin action and liver function. The work bridges basic science (animal models, tracer methodology) with clinical relevance to metabolic disease.
The episode reveals through rat tracer studies that peripheral insulin administration does not effectively deliver insulin to the liver, suggesting alternative mechanisms or barriers to hepatic insulin action that the field had previously overlooked.
The liver stores glucose in response to insulin during meals, serving as a critical buffer for blood glucose regulation.
The personal diagnosis with type 1 diabetes redirected the researcher's career focus toward investigating the specific mechanisms of insulin action and liver function.
Our reviewer’s read on each dimension, with quotes from the episode.
The transcript is severely fragmented and incoherent, making it impossible to extract meaningful insight. What few claims appear (liver glucose storage, a rat study) are presented without explanation, context, or substantive development. This reads like corrupted or heavily edited audio with no real educational content.
I mentioned my dad. But your father's actually a much bigger part of on that the rest of the field had clearly missed?
It can store a lot of glucose, which it does in response to insulin during a meal.
The transcript is too fragmented to assess originality. The few recognizable statements (insulin response, liver glucose storage) are textbook physiology with no novel framing, contrarian angle, or fresh perspective evident.
It can store a lot of glucose, which it does in response to insulin during a meal.
The transcript is so broken that speaker identity and credentials are unclear. A reference to 'your father' and 'a paper' suggests possible domain expertise, but there is zero evidence of operator-level experience, scale, or relevant accomplishment presented here.
your father's actually a much bigger part of on that the rest of the field had clearly missed?
But it also really changed my career focus.
The only semi-specific detail is a vague reference to a rat study ('laboratory rats'), but no author, publication, date, findings, or methodology are provided. No data, numbers, company names, or concrete evidence appears anywhere in this transcript.
published this paper where he showed this tracer on it, peripherally into a group of rats, laboratory rats, then they sectioned the animals
The transcript appears to be a corrupted or heavily truncated fragment of a conversation; it reads like audio with severe dropout or transcription failure. No clear questions, follow-ups, or dialogue structure is discernible, making assessment of conversational quality impossible.
So why is that important?
how do we to fix the This just happened to be
Computed from the transcript - who did the talking, and the words that came up most.
Send us Fan Mail The liver is the only organ in the body that can release stored glucose to prevent low blood sugar. So why has injected insulin never been able to reach it? In this clip from our episode “Finding a Solution for GLP-1 Side Effects”, host David E. Williams and Bob Geho, Founder and CEO of Diasome, break down the biological gap at the heart of diabetes treatment and how a father's decades of research into liver-targeted insulin delivery became the founding idea behind Diasome. Listen to the full episode here ️️ABOUT BOB GEHO Bob Geho is the Chief Executive Officer of Diasome Pharmaceuticals, a clinical-stage biopharmaceutical company developing portal-hepatic -targeted therapies designed to act at the source of metabolic regulation. Under his leadership, Diasome is advancing its proprietary Hepatocyte-Directed Vesicle (HDV) platform, which targets liver hepatocytes and the portal hepatic region, where metabolic control is centered. The company's lead clinical program, HDV-Insulin, applies this approach to insulin therapy - grounded in the principle that therapies working with the body's natural physiology may produce meaningfully better outcomes.
Transcribed and scored by The B2B Podcast Index.
So I, I, mentioned my dad. But your father's actually a much bigger part of on that the rest of the field had clearly missed? in the body of a rat. And so he published this paper where he showed this tracer on it, peripherally into a group of rats, laboratory rats, then they sectioned the animals and So why is that important?
It can store a lot of glucose, which it does in response to insulin during a meal. in, well, how do we to fix the This just happened to be, this just happened I wasn't thinking or wasn't aware of it. But no, I was diagnosed with type 1 diabetes But it also really changed my career focus.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
Success Leaves Clues: Ep 296 How Healthcare Innovation Improves Patient Access with John Leombruno, CEO at OkRx Success Leaves Clues with Robin Bailey and Al McDonald · on healthcare podcast79 / 100
🧬 Transforming Food Systems with Lactoferrin & Precision Fermentation | Fengru Lin Rerelease (3/3)The Biotech Startups Podcast · on Insulin72 / 100
Family Trauma & Business Success!Insights into Success · on Type 1 diabetes44 / 100
Biology Matters TrailerBiology Matters · on Diabetes31 / 100
From the Gap in Healthcare to a MovementWhat The Tech? · on healthcare
From Cambridge to Cabinet - Dr. Evis Sala, MD, PhD - Minister of Health and Social Protection of AlbaniaProgress, Potential, and Possibilities Podcast / Show · on healthcare
AI and The Future Of Behavioral Health w/ Alon Joffe, Co-Founder & CEO, Eleos Health88 / 100
How Targeted Radiotherapy Is Changing Cancer Care w/ John Babich, President, CSO, Ratio Therapeutics94 / 100
Preparing for the Pandemic We Haven't Seen Yet w/ Dr. Dan Barouch & Kris Brown, Vector Sciences87 / 100Mark Cuban on Why Patients Don’t Trust Their Medical Bills85 / 100
Why Healthcare Prices Are Like Fight Club w/ Mark Cuban, Co-Founder, Cost Plus Drugs100 / 100